Link Found Between Surgery and Development of Guillain-Barré

Share this content:
Link Found Between Surgery and Development of Guillain-Barré
Link Found Between Surgery and Development of Guillain-Barré

MONDAY, Nov. 28, 2016 (HealthDay News) -- Patients who've recently undergone surgery -- especially those with cancer or autoimmune diseases -- experience slightly higher risks of developing Guillain-Barré syndrome (GBS) soon afterward, according to a study published online Nov. 23 in Neurology: Clinical Practice.

Sara Hocker, M.D., an associate professor of neurology at the Mayo Clinic in Rochester, Minn., and colleagues reviewed the incidence of GBS in Mayo Clinic patients within two months of having a surgical procedure between 1995 and 2014. Those with postsurgical GBS were compared to patients who didn't undergo surgery prior to its onset.

Of the 208 total patients (average age, 55 years) who developed GBS in that time period, 31 had recently undergone surgery. The average time lapse between surgery and GBS onset was 19 days. Notably, 61 percent of those 31 patients had a known cancer diagnosis, while 29 percent had a diagnosis of an autoimmune condition, such as ulcerative colitis, type 1 diabetes, or rheumatoid arthritis.

"Surgical procedures antedated GBS in 15 percent of patients, which is unexpectedly high," the authors write. "History of malignancy or autoimmune disease may predispose to development of postsurgical GBS."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »